TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02478788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed amphetamine salts-extended release (MAS-XR)
Description: MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mixed amphetamine salts-extended release (MAS-XR)
Description: MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pills with no medication in it
Study: NCT04155554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: Switch patients from dolutegravir/lamivudine/abacavir to bictegravir/emtricitabine/tenefovir alafenamide to study neuropsychiatric side effects and neurocognitive function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir/lamivudine/abacavir
Description: Continuing dolutegravir/lamivudine/abacavir to study neuropsychiatric side effects and neurocognitive function
Study: NCT04832217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pyrenees´ Beef diet
Description: 24 participants were randomly assigned to a Pyrenees' beef diet, 3 serving per week during of 8 weeks.
Study: NCT01176175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
Study: NCT06005376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive
Description: The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast rolls consisting of wheat flour with and without a E304i/zinc additive
Description: The participants were provided with two Breakfast rolls (a 40 g) a day during the intervention week. In addition, they were provided with gluten-free foods during the whole trial.
Study: NCT01111929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Counseling for LAM+ LNG-EC
Description: They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Counseling for LAM+ LNG-EC
Description: They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.~They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer.
Study: NCT00814333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombin-JMI
Description: 5,000 IU, to nasal mucosa via syringe spray applicator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Merocel pack
Description: 8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
Study: NCT02850081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Standard of care treatment (one of four):~* Simvastatin (to 40mg without amlodipine)~* Simvastatin (to 20 mg if currently on amlodipine)~* Atorvastatin (to 80mg)~* Rosuvastatin (to 20mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: A lipid-lowering agent and for prevention of events associated with cardiovascular disease.~10 mg or 80 mg capsules

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
Study: NCT03720847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol Transdermal Patch 0.1 mg/24 hrs
Description: Estradiol transdermal patch delivering 0.1 mg/24 hour administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Micronized Progesterone
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Micronized Progesterone
Description: 100 mg oral micronized progesterone taken orally twice daily for 14 days starting day 7 after ovulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Clear Patch
Description: Matching placebo patch administered by affixing to skin for 14 days starting on day 7 after ovulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Matching placebo capsules administered twice daily for 14 days starting day 7 after ovulation
Study: NCT03975634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Spinal Stimulation
Description: Safety and feasibility will be monitored during transcutaneous spinal stimulation in children with spinal cord injury
Study: NCT01710085

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011
Description: Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
Study: NCT04109963

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning therapy to the upper arm will be delivered by an automated device (RIC VCI) manufactured by Seagull Aps (Denmark).
Study: NCT02785042

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heidelberg Spectralis OCT
Description: OCT imaging
Study: NCT02078466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of functional ability and follow-up at home
Description: Assessment of functional ability and follow-up at home
Study: NCT02734667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGM at diagnosis of T1D
Description: Initiation of non-adjunctive CGM use at diagnosis of T1D
Study: NCT01610193

Intervention type: PROCEDURE
Intervention: Appendicectomy
Description: Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
Study: NCT03834012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 800 µg per day
Description: Intervention: Drug: Beclomethasone 800 µg HFA per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intervention: Drug: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention: Drug: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone 400 µg per day
Description: Intervention: Drug: Beclomethasone 400 µg HFA per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone 640 µg per day
Description: Intervention: Drug: Beclomethasone 640 µg per day
Study: NCT01718496

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: patients with advanced COPD on the other study arm will randomly receive Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients with advanced COPD on the other study arm will randomly receive Placebo
Study: NCT02594111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine vs Placebo
Description: Colchicine vs Placebo 1.8 mg PO over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine vs Placebo
Description: Colchicine vs Placebo 1.8 mg PO over 1 hour
Study: NCT00662259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam (Xanax)
Description: Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, bid, p.o. for 28 +/- 2 days.
Study: NCT04250480

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta-alanine
Description: beta-alanine tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: rice powder tablet
Study: NCT02323438

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Brand Cigarette
Description: Combustible cigarette brand style smoked most frequently by subject

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #1
Description: Electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette #2
Description: Electronic cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Leading U.S. Nicotine Gum
Description: 4 mg nicotine polacrilex gum
Study: NCT01653418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Study: NCT02737618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trojan Chameleon Personal Lubricant
Description: silicone base with sensate
Study: NCT02871362

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IQP-AS-118
Description: Take one a day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one a day
Study: NCT05203016

Intervention type: OTHER
Intervention: Hipotermia/Normotermia
Description: The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.

Intervention type: OTHER
Intervention: Hipotermia/Normotermia
Description: The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.

Intervention type: OTHER
Intervention: Hipotermia/Normotermia
Description: The temperature will be measured at the beginning and at the end of the surgery, as well as during admission to the Post-Anesthesia Care Unit, where the temperature normalization time will be noted in the event of hypothermia. In retrospect, those variables corresponding to the late postoperative period will be evaluated and the telephone interview will be conducted to assess the quality of care received. All the data will be reflected in the collection booklet that we present in the annex.
Study: NCT01324752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 and Losartan with Food
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No PA21; Losartan with food
Description: The maximum dose of Losartan will be 100 mg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21 with food and Losartan 2 hours later
Description: The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
Study: NCT04678674

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tooth root augmentation
Description: Autogenous tooth roots for lateral alveolar ridge augmentation and staged implant placement.
Study: NCT02840565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
Study: NCT00486863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: 60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Made with the same color coded gelatin capsules with the inert compound dextrose.
Study: NCT02840565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
Study: NCT03870386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-BD with LAMS
Description: Endoscopic ultrasound guided insertion of lumen apposing metal stent forming a choledochoduodenostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography to localize and cannulate the bile duct using the guidewire-assisted technique.
Study: NCT02303054

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bipolar Radiofrequency Focal Ablation
Description: Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
Study: NCT04234217

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Suppression of lipolysis by niacin infusion
Study: NCT05589493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic full-arch rehabilitation using a PEEK-acrylic resin prosthesis
Description: A prosthetic full-arch rehabilitation of atrophic maxillae using a PEEk-acrylic resin prosthesis supported by dental implants following the All-on-4 Concept arrangement.
Study: NCT00968266

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient-centered group intervention
Description: Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent.
Study: NCT02931097

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulating deep brain electrodes and pulse generator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Stimulating deep brain electrodes and pulse generator

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Study: NCT01143792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA) + HIV prevention
Description: 12 sessions of the CRA and 2 sessions of HIV prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management + HIV Prevention
Description: 12 sessions of case management and 2 sessions of HIV prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Enhancement Therapy (MET) + HIV prevention
Description: 2 sessions of MET and 2 sessions of HIV prevention.
Study: NCT01859819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IT Cytarabine
Study: NCT00968266

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered group intervention
Description: Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.~Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent.